Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 14, Art. 68 (pp. 861-879)    |    2013       

»

Antiphospholipid syndrome

Koloskov A.V., 1,2,3 Philippova O.I., 1,2 Stolitsa A.A., 3 Bessmeltsev S.S. 4

SBIHE «Nord-Western State Medical University named after I.I. Mechnicov» under the Ministry of Public Health and Social Affairs of Russian Federation, St.Petersburg, Russia
2 City Hospital № 26, St.Petersburg, Russia
3 FSBI «Almazov federal heart, blood and endocrinology center»
Federal specialized perinatal center, St.Petersburg, Russia
4 FSBI «Russian Research Institute of Hematology and Transfusiology of FMBA Russia», St.Petersburg, Russia

Brief summary

Antiphospholipid syndrome is a systemic autoimmune disease associated with thrombosis and/or recurrent fetal loss in the setting of detectable antiphospholipid antibodies. The major antigenic target has been identifed as β2-glycoprotein I, which mediates binding of antiphospholipid antibodies to target cells including endothelial cells, monocytes, platelets and trophoblasts, leading to prothrombotic and proinfammatory changes that ultimately result in thrombosis and/or fetal loss. Since the establishment of the international preliminary classification and diagnostic criteria for antiphospholipid syndrome in 1999 was a considerable amount of work in the field of basic research, which provided new information. Clinical criteria of antiphospholipid syndrome were revised in Sydney in 2006. The mere presence of antiphospholipid antibodies does not mean the development of antiphospholipid syndrome in a patient. For the diagnosis of antiphospholipid syndrome requires the combination of at least one and one clinical laboratory test. Sydney criteria do not recommend using the term "secondary antiphospholipid syndrome." The studies failed to find differences in the clinical effects of the action of antiphospholipid antibodies in patients with primary and secondary antiphospholipid syndrome.


Key words

antiphospholipid syndrome, β2-glycoprotein I, clinical criteria

Reference list

1. Harris E. Syndrome of the black swan // Br. J. Rheumatol. – 1987. – V. 26. – P. 324–326.


2. Wilson W., Gharavi A., Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome // Arthritis Rheumotol. – 1999. – V.42. - P. 1309–1311.


3. Miyakis S., Lockshin M., Atusmi T. et al. International consensus statement on an update of the classification criteria for defnite antiphospholipid syndrome (APS) // J. Thromb. Haemost. -2006. – V. 4. – P. 295–306.


4. Fleck R., Rapaport S., Rao L. Anti-prothrombin antibodies and the lupus anticoagulant // Blood. – 1988. – V. 72. – V. 512–519.


5. McNeil H., Simpson R., Chesterman C., Krilis S. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H) // Proc. Natl. Acad. Sci. USA. – 1990. – V. 87. – P. 4120–4124.


6. Danowski A., Kickler T., Petri M. Anti-β2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus // J. Rheumatol. – 2006. – V. 33. – P. 1775–1779.


7. Lin W.S., Chen P.C., Yang C.D. et al // Some antiphospholipid antibodies recognize conformational epitopes shared by β2-glycoprotein I and the homologous catalytic domains of several serine proteases // Arthritis. Rheum. – 2007. – V. 56. – P. 1638–1647.


8. Harper B.E., Wills R., Pierangeli S.S. Pathophysiological mechanisms in antiphospholipid syndrome // Int. J. Clin. Rheumtol. – 2011. – V. 6. – P. 157–171.


9. Ruffatti A., Del Ross T., Ciprian M. et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study // Ann. Rheum. Dis. – 2009. – V. 68. – P. 397–399.


10. Danowski A., de Azevedo M., de Souza Papi J., Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus // J. Rheumtol. – 2009. – V. 36. – P. 1195–1199.


11. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature // Blood. – 2003. – V. 101. – P. 1827–1832.


12. de Groot P., Lutters B., Derksen R. et al. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis // J. Thromb. Haemost. – 2005. – V. 3. – P. 1993–1997.


13. 12. Cervera R., Khamashta M., Shoenfeld Y. et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients // Ann. Rheum. Dis. – 2009. – V. 68. – P. 1428–1432.


14. Bucciarelli S., Espinosa G., Cervera R. et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients // Arthritis Rheumotol. – 2006. – V. 54. – P. 2568–2576.


15. Miyakis S., Lockshin M.D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) // J. Thromb. Haemost. – 2006. – V. 4. – P. 295–306.


16. 13 Levine J.S., Branch D.W., Rauch J. The antiphospholipid syndrome // N. Engl. J. Med. – 2002. – V. 346. – P. 752–763.


17. Vianna J.L., Khamashta M.A., Ordi-Ros J. et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients // Am. J. Med. – 1994. – V. 96. – P. 3–9.


18. Salmon J.E., Girardi G., Holers V.M. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis // Ann. Rheum. Dis. – 2002. – V. 61. – P. ii46–50.


19. Girardi G., Redecha P., Salmon J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation // Nat. Med. – 2004.- V. 10. – P. 1222–1226.


20. Giannakopoulos B., Krilis S. A. The pathogenesis of antiphospholipid syndrome // N. E. J. Med. – 2013. – V. 368. – P. 1033–1044.


21. Evain-Brion D., Guibourdenche J., Tsatsaris V., Fournier T. Human trophoblast differentiation // Bull. Acad. Nat. Med. – 2009. – V. 193. – P. 1017–1025.


22. Mahler M., Norman G. L., Meroni P. L., Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome // Autoimm. Rev. – 2012. – V. 12. – P. 313–317.


23. de Groot P. G., Urbanus R. T. The significance of autoantibodies against 𝛽2-glycoprotein I // Blood. – 2012. – V. 120. – P. 266–274.


24. de Laat B., Pengo V., Pabinger I. et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study // J. Thromb. Haemost. – 2009. – V. 7. – P. 1767–1773.


25. Marchetti T., Cohen M., de Moerloose P. Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implications // Clin. Develop. Immun. Volume 2013, Article ID 159124, http://dx.doi.org/10.1155/2013/159124


26. van Horn J.T., Craven C., Ward K. et al. Histologic features of placentas and abortion specimens from women with antiphospholipid and antiphospholipis-like syndromes // Placenta. – 2004. – V. 25. – P. 642–648.


27. Skrzypczak J., Jasinski P., Wirstlein P. et al. Histologic changes in placenta and chorion of women with antiphospholipid syndrome and inherited thrombophilia // Ginekol. Polska. – 2011. – V. 82. – P. 652–663.


28. Shamonki J.M., Salmon J.E., Hyjek E., Baergen R.N. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies // Am. J. Obst. Gyn. – 2007. – V. 196. – P. 167.e1–167.e5.


29. Cavazzana I., Manuela N., Irene C. et al. Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? // J. Autoimm. – 2007. – V. 28. – P. 160–164.


30. Gerosa M., de Angelis V., Tresoidi L. et al. Complement involvement in antiphospholipid antibody-mediated placental damage: prospective study in APS pregnant women // Ann. Rheum. Dis. – 2009. – V. 68. - article 210.


31. Cohen D., Buurma A., Goemaere N.N. et al. Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss // J. Pathol. – 2011. – V. 225. – P. 502–511.


32. Girardi G., Berman J., Redecha P. et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome // J. Clin. Invest. – 2003. – V. 112. – P. 1644–1654.


33. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity // Immunity. – 2011. – V. 34. – P. 637–650.


34. Satta N., Kruithof E.K.O., Reber G., de Moerloose P. Induction of TLR2 expression by inflammatory stimuli is required for endothelial cell responses to lipopeptides // Molec. Immun. – 2008. – V. 46. – P. 145–157.


35. Dunoyer-Geindre S., de Moerloose P., Galve-de Rochemonteix B. et al. NF𝜅B is an essential intermediate in the activation of endothelial cells by anti-𝛽2-glycoprotein 1 antibodies // Thromb. Haemost. – 2002. – V. – 88. – P. 851–857.


36. E. Raschi, C. Testoni, D. Bosisio et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies // Blood. – 2003. – V. 101. – P. 3495– 3500.


37. Vega-Ostertag M., Casper K., Swerlick R. et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies // Arthritis Rheum. – 2005. – V. 52. – P. 1545–1554.


38. Satta N., Dunoyer-Geindre S., Reber G. et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies // Blood. – 2007. – V. 109. – P. 1507–1514.


39. Satta N., Kruithof E.K.O., Fickentscher C. et al. Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies // Blood. – 2001. – V. 117. – P. 5523–5531.


40. Poulton K., Rahman A., Giles I. Examining how antiphospholipid antibodies activate intracellular signaling pathways: a systematic review // Sem. Arthritis Rheum. – 2012. – V. 41. – P. 720–736.


41. Prinz N., Clemens N., Strand D. et al. Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells // Blood. – 2011. – V. 118. – P. 2322–2332.


42. Mulla M.J., Brosens J.J., Chamley L.W. et al. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway // Am. J. Reprod. Imm. – 2009. – V. 62. – P. 96–111.


43. Meroni P.L., Gerosa M., Raschi E. et al. Updating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss // Clin. Rev. Allerg. Imm. – 2008. – V. 34. – P. 332–337.


44. Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies // Nat. Rev. Rheum. – 2011. – V. 7. – P. 330–339.


45. Meroni P.L., Tedesco F., Locati M. et al. Anti-phospholipid antibody mediated fetal loss: Still an open question from a pathogenic point of view // Lupus. – 2010. – V. 19. – P. 453–456.


46. Mulla M.J., Myrtolli K., Brosens J.J. et al. Antiphospholipid antibodies limit trophoblast migration by reducing IL-6 production and STAT3 activity // Am. J. Reprod. Immun. – 2010. – V. 63. – P. 339–348.


47. Jovanovic M., Bozic M., Kovacevic T. et al. Effects of anti-phospholipid antibodies on a human trophoblast cell line (HTR-8/SVneo) // Acta Histochem. – 2010. – V. 112. – P. 34–41.


48. Adler R.R., Ng A.K., Rote N. S. Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR // Biol. Reprod. – 1995. – V. 53. – P. 905–910.


49. Di Simone N., Raschi E., Testoni C. et al. Pathogenic role of anti-𝛽2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of 𝛽2-glycoprotein I binding to trophoblast cells and functional effects of anti-𝛽2- glycoprotein I antibodies in vitro // Ann. Rheum. Dis. – 2005. – V. 64. – P. 462–467.


50. Francis J., Rai R., Sebire N. J. et al. Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome // Molec. Hum. Reprod. – 2006. – V. 12. – P. 435–442.


51. Gris J.C., Bouvier S., Molinari N. et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational Study // Blood. – 2012. – V. 119. – P. 2624–2632.


52. Cervera R., Piette J., Font J. et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients // Arthritis Rheum. – 2002. – V. 46. – P. 1019–1027.


53. Costedoat-Chalumeau N., Guettrot-Imbert G., Leguern V. et al. Pregnancy and antiphospholipid syndrome // Rev. Med. Inter. – 2012. – V. 33. – P. 209–216.


54. Nodler J., Moolamalla S. R., Ledger E. M. et al. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset // BMC Pregn. Child. – 2009. – V. 9. - article 11.


55. Rai R. S., Regan L., Clifford K. et al. Antiphospholipid antibodies and 𝛽2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach // Hum. Reprod. – 1995. – V. 10. – P. 2001–2005.


56. Mekinian A., Lachassine E., Nicaise-Roland P. et al. European registry of babies born to mothers with antiphospholipid syndrome // Ann. Rheum. Dis. – 2013. – V. 72. – P. 217–222.


57. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators and Centers for Disease Control and Prevention, “Prevalence of Autism


spectrum disorders—Autism and developmental disabilities monitoring network, 14 Sites, United States, 2008 // Morb. Mort. Week. Rep. – 2012. – V. 61. – P. 1–19.